https://oncbrain.oncologytoolkit.com/ AI-summarized oncology meeting studies, curated by a subspecialist. One item per study. en Sat, 30 May 2026 00:00:00 GMT https://oncbrain.oncologytoolkit.com/2026-05-30/#nrg-clinico-transcriptomic-prostate https://oncbrain.oncologytoolkit.com/2026-05-30/#nrg-clinico-transcriptomic-prostate Sat, 30 May 2026 00:00:00 GMT prostate [Early signal] 22-gene GC independently predicts MFS, DM, and OS; combined NRG score reclassifies ~25% discordant NCCN high-risk pts for AAP intensification. Eligible: NCCN ≥ high-risk localized prostate cancer, RT+ADT candidates https://oncbrain.oncologytoolkit.com/2026-05-20/#breast-pmrt-proton-vs-photon-cc https://oncbrain.oncologytoolkit.com/2026-05-20/#breast-pmrt-proton-vs-photon-cc Wed, 20 May 2026 00:00:00 GMT breast [Caveats dominate] MVA HR 1.76 (P=0.083) proton vs photon CC, non-significant; proton+DTI 2yr CC 50% vs photon+DTI 35%. Eligible: Post-mastectomy breast cancer, subpectoral TE/I or DTI reconstruction, PMRT cand https://oncbrain.oncologytoolkit.com/2026-05-19/#mmibc-tmt-bladder-preservation https://oncbrain.oncologytoolkit.com/2026-05-19/#mmibc-tmt-bladder-preservation Tue, 19 May 2026 00:00:00 GMT bladder [Confirmatory] CLR 63.7% in 369 MIBC pts on TMT; 5-FU-based CRT (OR 4.9) and portal imaging frequency independently predicted CLR. Eligible: cT2-T4aNOMO MIBC, median age 76, selected for organ-preserving TMT